Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.

Abu-Raddad, Laith J; Chemaitelly, Hiam; Yassine, Hadi M; Benslimane, Fatiha M; Al Khatib, Hebah A; Tang, Patrick; Malek, Joel A; Coyle, Peter; Ayoub, Houssein H; Al Kanaani, Zaina; +13 more... Al Kuwari, Einas; Jeremijenko, Andrew; Kaleeckal, Anvar Hassan; Latif, Ali Nizar; Shaik, Riyazuddin Mohammad; Abdul Rahim, Hanan F; Nasrallah, Gheyath K; Al Kuwari, Mohamed Ghaith; Al Romaihi, Hamad Eid; Al-Thani, Mohamed H; Al Khal, Abdullatif; Butt, Adeel A; Bertollini, Roberto; (2021) Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. Journal of travel medicine, 28 (7). taab083-. ISSN 1195-1982 DOI: https://doi.org/10.1093/jtm/taab083

Abstract

Key messages and recommendations Thispopulation-based study documentsBNT162b2vaccine protection week-by-week after the first dose. 75% of protection against infection and disease is reached 15-21 daysafter the first dose. Protection increased most rapidly against hospitalization and death and slowest against B.1.351infection.While protection of one dose beyond 21 days could not be assessed, findings support delaying the second vaccinedosein situations of limited vaccine suppliesand high incidences.

Additional Information

Item Type	Article
Faculty and Department	Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology (-2023)
Research Centre	Covid-19 Research
PubMed ID	34050372
Elements ID	161401